Form 8-K - Current report:
SEC Accession No. 0001213900-22-011854
Filing Date
2022-03-11
Accepted
2022-03-11 16:01:31
Documents
14
Period of Report
2022-03-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea156711-8k_jasperther.htm   iXBRL 8-K 36960
2 SERVICE AGREEMENT, DATED MARCH 7, 2022, BY AND BETWEEN JASPER THERAPEUTICS, INC. ea156711ex10-1_jasperther.htm EX-10.1 33574
  Complete submission text file 0001213900-22-011854.txt   302753

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE jspr-20220307.xsd EX-101.SCH 3939
4 XBRL DEFINITION FILE jspr-20220307_def.xml EX-101.DEF 27095
5 XBRL LABEL FILE jspr-20220307_lab.xml EX-101.LAB 37343
6 XBRL PRESENTATION FILE jspr-20220307_pre.xml EX-101.PRE 25717
8 EXTRACTED XBRL INSTANCE DOCUMENT ea156711-8k_jasperther_htm.xml XML 5889
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

EIN.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39138 | Film No.: 22733039
SIC: 2836 Biological Products, (No Diagnostic Substances)